Picture of Accustem Sciences logo

ACUT Accustem Sciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly Speculative

Momentum

Relative Strength (%)
1m+7.41%
3m+38.2%
6m+14.2%
1yrn/a
Volume Change (%)
10d/3m-20.67%
Price vs... (%)
52w High-69.33%
50d MA-22.7%
200d MA+4.76%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS  /

Blurred out image of Accustem Sciences EPS forecast chart

Profile Summary

AccuStem Sciences, Inc. is an early-stage life sciences company committed to developing and commercializing novel products for the treatment and management of many cancers. The principal activities of the Company are that of a genomics-based personalized medicine business, particularly focused on breast and lung cancer patients. Its product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company offers ancillary commodity testing (e.g., hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant.

Directors

    Last Annual
    Last Interim
    Incorporated
    January 1st, 1970
    Public Since
    January 1st, 1970
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq

    ACUT Share Price Performance

    Upcoming Events for ACUT

    Similar to ACUT

    Picture of 20/20 Genesystems logo

    20/20 Genesystems

    us flag iconPink Sheets on Nasdaq

    Picture of Aamaxan Transport logo

    Aamaxan Transport

    us flag iconPink Sheets on Nasdaq

    Picture of ADM Tronics Unlimited logo

    ADM Tronics Unlimited

    us flag iconPink Sheets on Nasdaq

    Picture of Agape ATP logo

    Agape ATP

    us flag iconPink Sheets on Nasdaq

    FAQ

    Or unlock with your email

    Or unlock with your email